C4 Therapeutics, Inc.

Contributing Author

Recent Articles by C4 Therapeutics, Inc.

16 hours	C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting CCCC GlobeNewswire
Aug-11	C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights CCCC +6.91% GlobeNewswire
Aug-10	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC GlobeNewswire
Jun-11	C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population CCCC GlobeNewswire
May-20	C4 Therapeutics to Participate in Upcoming Conferences CCCC +5.47% GlobeNewswire
May-18	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC -9.55% GlobeNewswire
May-12	C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Apr-09	C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) CCCC GlobeNewswire
Mar-25	C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma CCCC +7.60% GlobeNewswire
Mar-09	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC +18.09% CCCC -13.09% GlobeNewswire
Feb-26	C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Feb-23	C4 Therapeutics to Participate in Upcoming March Conferences CCCC +6.48% GlobeNewswire
Feb-23	C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma CCCC +6.48% GlobeNewswire
Feb-09	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC GlobeNewswire
Feb-04	C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 CCCC -5.97% GlobeNewswire
Jan-26	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC GlobeNewswire
Jan-14	C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways CCCC GlobeNewswire
Nov-25	C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference CCCC GlobeNewswire
Nov-06	C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Oct-16	C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering CCCC +11.71% GlobeNewswire
Oct-01	C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma CCCC GlobeNewswire
Sep-20	C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting CCCC GlobeNewswire
Sep-04	C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration CCCC GlobeNewswire
Sep-03	C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting CCCC GlobeNewswire
Aug-07	C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights CCCC +31.63% GlobeNewswire
May-07	C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights CCCC +6.38% GlobeNewswire

C4 Therapeutics, Inc.

Recent Articles by C4 Therapeutics, Inc.

Upgrade your Finviz experience